About the Company
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
380
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALLO News
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call Transcript March 14, 2024 Allogene Therapeutics, Inc. isn’t one of the 30 most popular stocks among ...
Allogene Therapeutics Poised for Growth: A Strong Buy Rating Amidst Innovative Trials and Strategic Advancements
Jack Allen, an analyst from Robert W. Baird, maintained the Buy rating on Allogene Therapeutics (ALLO – Research Report). The associated ...
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Consolidation Trial in Large B-Cell Lymphoma (LBCL): Start-Up Activities Underway; Enrollment to Begin Mid-2024Cema-cel Phase ...
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
Allogene Therapeutics, Inc. ALLO incurred an adjusted loss (excluding impairment of long-lived asset) of 43 cents per share in fourth-quarter 2023, narrower than the Zacks Consensus Estimate of a loss ...
Allogene Therapeutics: Advancing Clinical Studies and Promising Treatment Differentiation Set Stage for Stock Value Growth
Analyst John Newman of Canaccord Genuity maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a price target ...
Allogene Therapeutics: Q4 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. — SOUTH SAN FRANCISCO, Calif. — Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $85.8 million in its fourth quarter. The South San Francisco, ...
Allogene, Arbor Announce Global Gene Editing Licensing Agreement For CAR T Platform
(RTTNews) - Allogene Therapeutics, Inc. (ALLO) and Arbor Biotechnologies, Inc. on Tuesday announced that they have entered into a non-exclusive, global gene editing licensing agreement. The ...
Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
March 14, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and ...
Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript
Thank you for standing by and welcome to Allogene Therapeutics Fourth Quarter and Full Year 2023 Conference Call. At this time, all participants are in a listen-only mode. After the speaker ...
Loading the latest forecasts...